Drugs / simlukafusp alfa
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03875079 | Jun 2019 → Jul 2022 | metastatic melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03063762 | Mar 2017 → Jun 2021 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02627274 | Dec 2015 → Nov 2022 | breast cancer, head and neck cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT03386721 | Feb 2018 → Dec 2021 | — | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT03768063 | Feb 2019 → Jul 2028 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | Cellectis S.A. | Results Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 cellectis.com ↗
CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN-edited allogeneic CAR T-cells without associated IL-2 toxicity |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | Cellectis S.A. | Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 cellectis.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simlukafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03386721 ↗ |
| Known as | FAP-IL2v | “BACKGROUND: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment.” PMID 39395231 ↗ Oct 2024 |
| Known as | FAP-IL2V FP RO6874281 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298090 ↗ |
| Known as | RG-7461 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298090 ↗ |
| Known as | RO6874281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03193190 ↗ |
| Modality | Protein / enzyme biologic | “RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v)” NCT02627274 ↗ |
| Route | Intravenous | “RO6874281 will be administered as an intravenous (IV) infusion.” NCT02627274 ↗ |
| Target | FAP | “Targeting Fibroblast Activation Protein-α (FAP)” NCT02627274 ↗ |